TVA Medical
Medical device company developing innovative, minimally invasive therapies for the treatment of end stage renal disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
$7.0m | Debt | ||
| Total Funding | 000k | ||
Related Content
TVA Medical specializes in innovative medical devices for vascular access, particularly for patients with End Stage Kidney Disease (ESKD). The company's flagship product, the 4F EndoAVF System, offers a non-surgical alternative for creating arteriovenous (AV) fistulas, which are essential for hemodialysis. This system minimizes surgical scarring and arm disfigurement, providing multiple venous procedural approaches and additional anatomical AV fistula locations. TVA Medical primarily serves healthcare providers and patients requiring vascular access for dialysis. Operating in the medical device market, the company generates revenue through the sale of its proprietary EndoAVF systems and related accessories. The business model focuses on improving patient outcomes and reducing the complications associated with traditional surgical methods.
Keywords: AV fistula, non-surgical, hemodialysis, ESKD, vascular access, medical device, endovascular, scarring, dialysis, healthcare.